 |
|
Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis
Stephen J. Nicholls, MBBS, PhD;
E. Murat Tuzcu, MD;
Ilke Sipahi, MD;
Adam W. Grasso, MD;
Paul Schoenhagen, MD;
Tingfei Hu, MS;
Kathy Wolski, MPH;
Tim Crowe, BS;
Milind Y. Desai, MD;
Stanley L. Hazen, MD, PhD;
Samir R. Kapadia, MD;
Steven E. Nissen, MD
JAMA. 2007;297:499-508.
Context Statins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow progression of coronary atherosclerosis. However, no data exist describing the relationship between statin-induced changes in high-density lipoprotein cholesterol (HDL-C) and disease progression.
Objective To investigate the relationship between changes in LDL-C and HDL-C levels and atheroma burden.
Design, Setting, and Patients Post-hoc analysis combining raw data from 4 prospective randomized trials (performed in the United States, North America, Europe, and Australia between 1999 and 2005), in which 1455 patients with angiographic coronary disease underwent serial intravascular ultrasonography while receiving statin treatment for 18 months or for 24 months. Ultrasound analysis was performed in the same core laboratory for all of the studies.
Main Outcome Measure Relationship between changes in lipoprotein levels and coronary artery atheroma volume.
Results During statin therapy, mean (SD) LDL-C levels were reduced from 124.0 (38.3) mg/dL (3.2 [0.99] mmol/L) to 87.5 (28.8) mg/dL (2.3 [0.75] mmol/L) (a 23.5% decrease; P<.001), and HDL-C levels increased from 42.5 (11.0) mg/dL (1.1 [0.28] mmol/L) to 45.1 (11.4) mg/dL (1.2 [0.29] mmol/L) (a 7.5% increase; P<.001). The ratio of LDL-C to HDL-C was reduced from a mean (SD) of 3.0 (1.1) to 2.1 (0.9) (a 26.7% decrease; P<.001). These changes were accompanied by a mean (SD) increase in percent atheroma volume from 39.7% (9.8%) to 40.1% (9.7%) (a 0.5% [3.9%] increase; P = .001) and a mean (SD) decrease in total atheroma volume of 2.4 (23.6) mm3 (P<.001). In univariate analysis, mean levels and treatment-mediated changes in LDL-C, total cholesterol, non-HDL cholesterol, apolipoprotein B, and ratio of apolipoprotein B to apolipoprotein A-I were significantly correlated with the rate of atherosclerotic progression, whereas treatment-mediated changes in HDL-C were inversely correlated with atheroma progression. In multivariate analysis, mean levels of LDL-C ( coefficient, 0.11 [95% confidence interval, 0.07-0.15]) and increases in HDL-C ( coefficient, –0.26 [95% confidence interval, –0.41 to –0.10]) remained independent predictors of atheroma regression. Substantial atheroma regression ( 5% reduction in atheroma volume) was observed in patients with levels of LDL-C less than the mean (87.5 mg/dL) during treatment and percentage increases of HDL-C greater than the mean (7.5%; P<.001). No significant differences were found with regard to clinical events.
Conclusions Statin therapy is associated with regression of coronary atherosclerosis when LDL-C is substantially reduced and HDL-C is increased by more than 7.5%. These findings suggest that statin benefits are derived from both reductions in atherogenic lipoprotein levels and increases in HDL-C, although it remains to be determined whether the atherosclerotic regression associated with these changes in lipid levels will translate to meaningful reductions in clinical events and improved clinical outcomes.
Author Affiliations: Departments of Cardiovascular Medicine (Drs Nicholls, Tuzcu, Sipahi, Grasso, Schoenhagen, Desai, Hazen, Kapadia, and Nissen, Messrs Hu and Crowe, and Ms Wolski), Cell Biology (Drs Nicholls and Hazen), and Diagnostic Radiology (Dr Schoenhagen), and Center for Cardiovascular Diagnostics and Prevention (Drs Nicholls and Hazen), Cleveland Clinic, Cleveland, Ohio.
RELATED LETTERS
Statins and Regression of Coronary Atherosclerosis
Vasilios G. Athyros, Anna Kakafika, Asterios Karagiannis, and Dimitri P. Mikhailidis
JAMA. 2007;297(20):2197.
EXTRACT
| FULL TEXT
Statins and Regression of Coronary Atherosclerosis—Reply
Stephen J. Nicholls, E. Murat Tuzcu, and Steven E. Nissen
JAMA. 2007;297(20):2197.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk
Thompson et al.
JAMA 2008;299:2777-2788.
ABSTRACT
| FULL TEXT
Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography: A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden
Ballantyne et al.
Circulation 2008;117:2458-2466.
ABSTRACT
| FULL TEXT
Do the extent and direction of arterial remodelling predict subsequent progression of coronary atherosclerosis? A serial intravascular ultrasound study
Sipahi et al.
Heart 2008;94:623-627.
ABSTRACT
| FULL TEXT
Laboratory Assessment of HDL Heterogeneity and Function
Movva and Rader
Clin. Chem. 2008;54:788-800.
ABSTRACT
| FULL TEXT
Increased High-Density Lipoprotein Cholesterol Predicts the Pioglitazone-Mediated Reduction of Carotid Intima-Media Thickness Progression in Patients With Type 2 Diabetes Mellitus
Davidson et al.
Circulation 2008;117:2123-2130.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT
Letter Regarding Article by Leeper et al, "Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival"
Anderson and Salgado
Circulation 2008;117:e174-e174.
FULL TEXT
HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
Barter et al.
NEJM 2007;357:1301-1310.
ABSTRACT
| FULL TEXT
Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials
Lincoff et al.
JAMA 2007;298:1180-1188.
ABSTRACT
| FULL TEXT
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT
| FULL TEXT
JournalScan
Lindsay
Heart 2007;93:773-774.
FULL TEXT
Statins and Regression of Coronary Atherosclerosis
Athyros et al.
JAMA 2007;297:2197-2197.
FULL TEXT
Statin Therapy and Atherosclerosis Regression
JWatch General 2007;2007:2-2.
FULL TEXT
|
